Liao, A.-H.A.-H.LiaoWu, S.-Y.S.-Y.WuWeng, C.-H.C.-H.WengWang, H.-E.H.-E.WangPAI-CHI LI2020-04-162020-04-162009https://scholars.lib.ntu.edu.tw/handle/123456789/484574Targeted albumin shelled microbubbles (MBs) have been applied as a potential drug carrier for the treatment of cancer cells. To provide the pharmacokinetics of the targeted albumin MBs for in vivo therapeutic use of cancer therapy, the multimodality N-succinimidyl-4- [18F] fluorobenzoate (18F-SFB) labeled tumor angiogenesis-related vascular endothelial growth factor receptor 2 (VEGFR2) targeted MBs (tMBs) were synthesized and the biologic characteristics of the tMBs in MDA-MB-231 human breast-cancer-bearing mice were investigated with micro-positron emission tomography (microPET) and high frequency ultrasound (microUS). The efficiency of tMBs targeted to tumor vascular was 14.8% rather than MBs in contrast enhanced microUS. The 18F-labeled tMBs were cleared from blood circulation and accumulated in liver (16.3% ID/g ± 6.8) and lung (5.7 ID/g ±1.6) at 60minutes. Uptake of 18F-labele tMBs was significantly higher in tumor (1.02% ID/g ± 0.3) than in surrounding muscle tissue (0.4% ID/g ± 0.02) at 60minutes. The findings were confirmed with ex vivo biodistribution study. Therefore, 18F-SFB labeled VEGFR2-targeted MBs showed specific tumor uptake in human breast-cancer-bearing mice and could be used as a probe for delivery vehicles in cancer treatment. This study provides useful information for the future clinical application of the multimodality material from imaging to therapeutic levels. ?2009 IEEE.[SDGs]SDG3Cardiovascular system; Diseases; Mammals; Tumors; Clinical application; Contrast-enhanced; High frequency ultrasounds; Human breast cancer; Micro positron emission tomography; Therapeutic levels; Tumor angiogenesis; Vascular endothelial growth factor receptor; Positron emission tomographyconference paper10.1109/ULTSYM.2009.54419522-s2.0-77952815328https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952815328&doi=10.1109%2fULTSYM.2009.5441952&partnerID=40&md5=c1902cfbd8d740e8487374fd6119fe8a